Long-term Efficacy and Safety of Brodalumab in Patients With or Without History of Psoriatic Arthritis: Analysis of Two Phase 3 Psoriasis Studies

Alice Gottlieb; Alan Menter; Paul Yamauchi; George Han; Radhakrishnan Pillai; Tina Lin; Abby Jacobson

doi:10.25251/skin.3.supp.21

Alice Gottlieb

Icahn School of Medicine at Mount Sinai, New York, NY

Alan Menter

Baylor Scott & White, Dallas, TX

Paul Yamauchi

Dermatology Institute & Skin Care Center, Santa Monica, CA

George Han

Icahn School of Medicine at Mount Sinai, New York, NY

Radhakrishnan Pillai

Bausch Health Americas, Petaluma, CA

Tina Lin

Ortho Dermatologics, Bridgewater, NJ

Abby Jacobson

Ortho Dermatologics, Bridgewater, NJ

Keywords

psoriasis, brodalumab

Abstract

Abstract not available.

References

1. Gottlieb et al. J Am Acad Dermatol. 2008;58:851-864.

2. Siliq [package insert]. Bridgewater, NJ: Valeant
Pharmaceuticals North America, LLC; 2017.

3. Lebwohl et al. N Engl J Med. 2015;373:1318-1328.

4. Menter et al. Poster presented at the 2017 Fall Clinical Dermatology Conference; October 12-15, 2017; Las Vegas, NV.

Poster PDF

Published

Nov 9, 2019

DOI https://doi.org/10.25251/skin.3.supp.21

How to Cite

[1]

Gottlieb, A., Menter, A., Yamauchi, P., Han, G., Pillai, R., Lin, T. and Jacobson, A. 2019. Long-term Efficacy and Safety of Brodalumab in Patients With or Without History of Psoriatic Arthritis: Analysis of Two Phase 3 Psoriasis Studies. SKIN The Journal of Cutaneous Medicine. 3, (Nov. 2019), S21. DOI:https://doi.org/10.25251/skin.3.supp.21.

Issue

Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas

Section

Poster Presentations from FC23 Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Jerry Bagel, Yipeng Wang, Paul Montgomery, III, Christian Abaya, Eric Andrade, Courtney Boyce, Tatiana Tomich, Byung-In Lee, David Pariser, Alan Menter, Tobin Dickerson, A Machine Learning-Based Test for Predicting Response to Psoriasis Biologics , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Graham H Litchman DO, MS, Quinn Thibodeaux, Ryan Rivera-Oyola, John Koo, Rick Fried, Gary Goldenberg, George Han, Sylvia Hsu, Leon Kircik, Melissa Knuckles, Andrea Murina, Jashin Wu, Mark Lebwohl, Should Package Insert Warnings Deter Prescribing in Psoriasis Patients with Depression? , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
Mark Lebwohl, Leon Kircik, Angela Moore, Linda Stein Gold, James Del Rosso, Zoe Draelos, Melinda Gooderham, Lawrence Green, Adelaide Herbert, Kim Papp, Jerry Bagel, Neal Bhatia, Laura Ferris, Terry Jones, Steve Kempers, David Pariser, Paul Yamauchi, Matthew Zirwas, Amy Feng, Patrick Burnett, Robert Higham, David Berk, Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Quinn Thibodeaux, Rick Fried, Gary Goldenberg, George Han, Sylvia Hsu, Leon Kircik, Melissa Knuckles, Mark Lebwohl, Graham Litchman, Andrea Murina, Ryan Rivera-Oyola, Jeffrey Weinberg, Jashin J Wu, John Koo, Expert Panel Discussion among Psoriasis and Psychodermatology Specialists: How Best to Manage Depressed Psoriasis Patients with Brodalumab , SKIN The Journal of Cutaneous Medicine: Vol. 3 No. 6 (2019)
Richard Warren, Howard Sofen, Shinichi Imafuku, Jacek Szepietowski, Andrew Blauvelt, Lynda Spelman, Jessica Toms, Alex Buck, Subhashis Banerjee, Alan Menter, Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Alan Menter, Andrew Blauvelt, Bruce Strober, Matthew Colombo, Renata Kisa, Sudeep Kundu, Subhashis Banerjee, Craig Leonardi, Deucravacitinib (BMS-986165), an Oral, Allosteric Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement and Improves Quality of Life in Patients With Psoriasis , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Linda Stein Gold, Mark Lebwohl, Neal Bhatia, Douglas DiRuggiero, Abby Jacobson, Radhakrishnan Pillai, Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Matthew Zirwas, Zoe Draelos, Janet Dubois, Leon Kircik, Angela Moore, Linda Stein Gold, Javier Alonso-Llamazares, Michael Bukhalo, Suzanne Bruce, Kimmie Eads, Lawrence Green, Scott Guenthner, Laura Ferris, Seth Forman, Steven Kempers, Edward Lain, Charles Lynde, David Pariser, David Pariser, Darryl Toth, paul Yamauchi, Patrick Burnett, David Berk, A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Mark Lebwohl, Richard B. Warren, Howard Sofen, Shinichi Imafuku, Carle Paul, Jacek C. Szepietowski, Lynda Spelman, Thierry Passeron, Elizabeth Colston, Lauren Hippeli, Andrew Napoli, Renata M. Kisa, Subhashis Banerjee, Alan Menter, Diamant Thaçi, Andrew Blauvelt, Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Jerry Bagel, Linda Stein Gold, James Del Rosso, Neal Bhatia, Sandy Johnson , Paul Yamauchi, Angela Moore, Anna Tallman, Patient Satisfaction with Tapinarof Cream 1% Once Daily for Plaque Psoriasis in a Long-Term Extension Trial , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)

1 2 3 4 5 6 7 8 9 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)